Vanguard Group Inc. Has $1.14 Billion Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Vanguard Group Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,158,926 shares of the medical research company’s stock after buying an additional 60,497 shares during the period. Vanguard Group Inc. owned about 0.12% of Charles River Laboratories International worth $1,136,938,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $3,600,000. Sei Investments Co. raised its stake in Charles River Laboratories International by 6.1% during the fourth quarter. Sei Investments Co. now owns 673,868 shares of the medical research company’s stock worth $124,394,000 after buying an additional 38,827 shares during the last quarter. American Century Companies Inc. boosted its position in Charles River Laboratories International by 5.6% during the fourth quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company’s stock valued at $551,000 after acquiring an additional 157 shares during the last quarter. Quantbot Technologies LP grew its holdings in Charles River Laboratories International by 13.8% during the 4th quarter. Quantbot Technologies LP now owns 9,300 shares of the medical research company’s stock worth $1,717,000 after acquiring an additional 1,131 shares during the period. Finally, Royal London Asset Management Ltd. raised its position in shares of Charles River Laboratories International by 6.4% in the 4th quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company’s stock worth $3,032,000 after acquiring an additional 991 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Down 1.6 %

Shares of NYSE:CRL opened at $155.60 on Friday. The stock has a market cap of $7.96 billion, a price-to-earnings ratio of 1,037.35, a PEG ratio of 4.54 and a beta of 1.45. The business’s 50 day moving average is $164.69 and its 200 day moving average is $182.73. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $273.32. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.46 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research analyst reports. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).